Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477230 · ClinicalTrials.gov registry record · Phase 3
Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs
A Phase 3 study, sponsored by CardioFocus.
- Terminated
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT00477230 is a Phase 3 study that was terminated before completion, run by CardioFocus. The registered enrollment target is 64 participants.
The verdict
NCT00477230, a Phase 3 study, was terminated before completion, sponsored by CardioFocus.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of the study is to compare two types of treatment for atrial fibrillation (AF) that are designed to treat the symptoms of atrial fibrillation. The treatments being compared are: * A single catheter ablation procedure with the investigational EAS, a visually-guided, light-energy catheter * Standard drug therapy (antiarrhythmic drugs) To learn more about the CardioFocus ENABLE investigational clinical study, please contact the study site closest to you. Eligibility Criteria Persons with paroxysmal atrial fibrillation may be eligible for this study. Other study eligibility criteria include: * 18 to 80 years of age * Frequent episodes of AF * Failed at least 1 drug treatment for AF (beta-blockers or standard AADs) * Other criteria
Interventions
- DEVICE Endoscopic Ablation System
- DRUG Standard Anti-arrhythmic Drug (AAD) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477230
The ClinicalTrials.gov registry entry for NCT00477230 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioFocus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Endoscopic Ablation System is the first listed.
NCT00477230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477230 about?
NCT00477230 is a clinical study titled "Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs". The purpose of the study is to compare two types of treatment for atrial fibrillation (AF) that are designed to treat the symptoms of atrial fibrillation. The treatments being compared are: * A single catheter ablation procedure with the investigational EAS, a visually-guided, light-energy catheter...
What is the current status of trial NCT00477230?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2007-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00477230?
The interventions under investigation include: Endoscopic Ablation System (DEVICE), Standard Anti-arrhythmic Drug (AAD) Therapy (DRUG).
Who is sponsoring clinical trial NCT00477230?
This trial is sponsored by CardioFocus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.